You can use your existing Medical Independent, MediLearning or PharmacistCPD account to log in. is Ireland's only investigative medical news website for doctors, healthcare professionals and anyone with an interest in health issues.

Established in 2010, along with its sister publication The Medical Independent, our stated aim is to investigate and analyse the major issues affecting healthcare and the medical profession in Ireland. The Medical Independent has won a number of awards for its investigative journalism, and its stories are frequently picked up by national digital, broadcast and print media. The Medical Independent is published by GreenCross Publishing.

Address: Top Floor, 111 Rathmines Road Lr, Dublin 6

Tel: 353 (01) 441 0024

GreenCross Publishing is owned by Graham Cooke.

The benefits of registering: only registered users:
  • receive the ecCopy two days prior to the printed edition.
  • have automatic access to our free CPD sites.
  • can partake in our online MCQs.
  • can enter our online sports quiz.

Sign up now for ease of access to The Medical Independent, Ireland’s most frequently published medical newspaper, delivering award-winning news and investigative reporting.

Download the new Mindo app for both IOS & Android.

  • Get notified when a story goes live
  • Access Premium Content
  • Read Offline
[the_ad_placement id="main-ldb-public"]
[the_ad_placement id="main-ldb-mobile-public"]

You are reading 1 of 2 free-access articles allowed for 30 days

Clinical perspectives on melanoma

By Dermot - 23rd Nov 2020 | 15 views

doctor doing a dermoscopy dermoscopy prevention on a female patient in his office.

Gathering Around Cancer, virtual meeting, 5-6 November 2020

The Gathering Around Cancer conference also heard from Dr Fergal Kelleher, Consultant Oncologist at St James’s Hospital in Dublin, who delivered a talk titled ‘Melanoma update’. Dr Kelleher provided an overview of some trial data from a number of studies and said that it is often the case in trials that there are an insufficient number of events to perform an overall analysis. However, one five-year study on patients with resected stage 3 melanoma, the COMBI-i trial, showed that 12 months of adjuvant therapy dabrafenib plus trametinib resulted in a longer duration of survival without relapse or distant metastases than placebo, with no apparent longterm toxic effects.

Dr Kelleher also reported on the CheckMate 238 phase 3 trial, which showed a 1:1 ratio of treatment with adjuvant nivolumab vs adjuvant dupilumab and demonstrated improvement in survival for nivolumab vs dupilumab, as well as an improvement in distant metastases-free survival for nivolumab. Only 211 of the anticipated 302 overall survival events were observed at four years, said Dr Kelleher, with a statistical difference between the treatment groups in terms of survival. He also touched on the KEYNOTE-054 trial, which showed that in five-year median follow-up, adjuvant pembrolizumab prolonged progression-free survival, with a hazard ratio of 0.57 and a highly statistically-significant P value compared to placebo. Dr Kelleher also presented case studies and told the conference: “It’s really important that we have these adjuvant therapies available to us, because melanoma really has a proclivity to disperse widely.”

It’s really important that we have these adjuvant therapies available to us, because melanoma really has a proclivity to disperse widely

In the metastatic setting, he said “there has always been a difficulty with the combination of immunotherapy and molecularly-targeted agents in melanoma” due to the potential for severe hepatotoxicity. However, he drew attention to a study on a triplet regimen – the IMspire150 trial – which was published recently in Lancet Oncology. This was the first trial of its kind to demonstrate that it is possible to successfully combine immunotherapy and molecularly-targeted agents for metastatic melanoma or unresectable stage 3 melanoma and is “a real finding and a true advance in the treatment of this disease”

Leave a Reply

[the_ad_placement id="main-ldb-public-2"]
[the_ad_placement id="main-ldb-mobile-public-2"]
Latest Issue
The Medical Independent – 24 June 2021

You need to be logged in to access this content. Please login or sign up using the links below.

[the_ad_placement id="main-mpu-public"]
Most Read
[the_ad_placement id="main-ldb-public-2"]
[the_ad_placement id="main-ldb-mobile-public-2"]